Atara Biotherapeutics (ATRA) Operating Expenses (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Operating Expenses came in at $3.9 million in Q1 2026, down 93.45% YoY from $59.3 million in Q1 2025, and down 6.57% on a QoQ basis from $4.2 million in Q4 2025.
Atara Biotherapeutics (ATRA) Operating Expenses (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Operating Expenses data on file, last reported at $3.9 million in Q1 2026.
- Quarterly Operating Expenses fell 93.45% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.4 million (down 86.18% YoY) and the FY2025 annual result came in at $84.9 million, down 60.02% from the prior year.
- Operating Expenses slipped to $3.9 million in Q1 2026, from $4.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $95.5 million in Q1 2022 to a low of $3.9 million in Q1 2026.
- A 5-year average of $54.7 million and a median of $61.9 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses gained 16.79% — and 2026, when it slumped 93.45%.
- Tracing ATRA's Operating Expenses over 5 years: stood at $75.8 million in 2022, then declined by 15.24% to $64.2 million in 2023, then decreased by 29.99% to $45.0 million in 2024, then tumbled by 90.75% to $4.2 million in 2025, then fell by 6.57% to $3.9 million in 2026.
- The last three Operating Expenses figures came in at $3.9 million (Q1 2026), $4.2 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Atara Biotherapeutics | 140.71 Mn | 124.16 Mn | 439,000.00 | 5.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.35 Mn |
| Mar 31, 2026 | 3.89 Mn |
| Dec 31, 2025 | 4.16 Mn |
| Sep 30, 2025 | 7.03 Mn |
| Jun 30, 2025 | 14.38 Mn |
| Mar 31, 2025 | 59.35 Mn |
| Dec 31, 2024 | 44.96 Mn |
| Sep 30, 2024 | 61.95 Mn |
| Jun 30, 2024 | 46.87 Mn |
| Mar 31, 2024 | 58.60 Mn |
| Dec 31, 2023 | 64.21 Mn |
| Sep 30, 2023 | 71.75 Mn |
| Jun 30, 2023 | 72.37 Mn |
| Mar 31, 2023 | 76.24 Mn |
| Dec 31, 2022 | 75.76 Mn |
| Sep 30, 2022 | 89.08 Mn |
| Jun 30, 2022 | 83.71 Mn |
| Mar 31, 2022 | 95.53 Mn |
| Dec 31, 2021 | 100.95 Mn |
| Sep 30, 2021 | 90.18 Mn |